Gilead Sciences, Inc. (GILD), AbbVie Inc (ABBV): Which Company Needs a HCV Win?

Page 1 of 2

The upcoming all-oral hepatitis C treatments earned well-deserved attention for some staggering cure rates, particularly in patient groups who haven’t responded well to the current drugs. Merck & Co., Inc. (NYSE:MRK) was one of the big HCV players — but that’s about to change with Gilead Sciences, Inc. (NASDAQ:GILD) and AbbVie Inc (NYSE:ABBV) leading the new guard. How much does an HCV foothold mean to the overall health of these companies?

Gilead Sciences, Inc. (NASDAQ:GILD)

Defending champion falls flat

The combo therapy used for most patients with ongoing HCV involves an interferon injection and the oral drug ribavirin. But patients with genotype 1 — the most common genotype in the United States — require the addition of a protease inhibitor to achieve the best possible cure rates.

Merck & Co., Inc. (NYSE:MRK) has historically held a front position in the HCV market with the ribavirin Rebetol, the branded interferon PegIntron, and the protease inhibitor Victrelis. But generic ribavirin became available nearly a decade ago — and Merck & Co., Inc. (NYSE:MRK)’s lost most of its other ground to competitors.

PegIntron hit peak sales of $914 million in 2008 when Schering Plough was still independent. Sales last year had fallen to $653 million due to the rise of Roche’s competing Pegasys, which had 2012 sales of about $1.7 billion (using current exchange rates).

Victrelis was much faster at succumbing to competition. The drug launched concurrently with Vertex’s protease inhibitor Incivek in 2011. Incivek quickly took the market with sales of $950 million in 2011 and $1.16 billion in 2012. Victrelis had sales of $140 million and $502 million, respectively. But both protease inhibitors could suffer a massive drop when the all-oral drugs hit the market.

New guard’s drug dependence

Three companies have reported the best cure rates for genotype 1 patients: Gilead Sciences, Inc. (NASDAQ:GILD), AbbVie Inc (NYSE:ABBV), and Johnson and Johnson.

Let’s turn first to Gilead Sciences, Inc. (NASDAQ:GILD)’s sofosbuvir. The drug received a priority review designation from the Food and Drug Administration last month and has an expected PDUFA date of December 8.. Analyst estimates for sofosbuvir average out to around $6 billion by 2016, according to Bloomberg.

Gilead Sciences, Inc. (NASDAQ:GILD)’s total products sales were $9.4 billion last year and that included over a dozen products. The company’s portfolio includes a strong batch of HIV drugs, while the pipeline also features some promising cancer candidates.

AbbVie Inc (NYSE:ABBV)’s unnamed oral combo-therapy is running slightly behind Gilead Sciences, Inc. (NASDAQ:GILD) in the pipelines, but AbbVie Inc (NYSE:ABBV)’s in greater need of a win.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Top 10 Highest Paying Jobs in the World

Most Expensive Day-Care in New York City

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!